Nevro Corp NVRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVRO is a good fit for your portfolio.
News
-
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
-
Nevro Enters Into Cooperation Agreement With Engaged Capital
-
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
-
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
-
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
-
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
-
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
-
Nevro laying off 63 employees; revenue to beat analyst estimates
Trading Information
- Previous Close Price
- $13.57
- Day Range
- $13.61–14.54
- 52-Week Range
- $13.36–39.68
- Bid/Ask
- $12.80 / $22.00
- Market Cap
- $524.86 Mil
- Volume/Avg
- 290,896 / 489,356
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,215
- Website
- https://www.nevro.com
Comparables
Valuation
Metric
|
NVRO
|
MMSI
|
SIBN
|
---|---|---|---|
Price/Earnings (Normalized) | — | 25.07 | — |
Price/Book Value | 1.79 | 3.63 | 3.80 |
Price/Sales | 1.22 | 3.50 | 4.38 |
Price/Cash Flow | — | 20.47 | — |
Price/Earnings
NVRO
MMSI
SIBN
Financial Strength
Metric
|
NVRO
|
MMSI
|
SIBN
|
---|---|---|---|
Quick Ratio | 4.82 | 3.81 | 8.01 |
Current Ratio | 6.37 | 5.45 | 9.01 |
Interest Coverage | −12.98 | 8.07 | −13.52 |
Quick Ratio
NVRO
MMSI
SIBN
Profitability
Metric
|
NVRO
|
MMSI
|
SIBN
|
---|---|---|---|
Return on Assets (Normalized) | −5.64% | 9.43% | −8.97% |
Return on Equity (Normalized) | −11.08% | 14.77% | −12.61% |
Return on Invested Capital (Normalized) | −7.81% | 11.47% | −11.78% |
Return on Assets
NVRO
MMSI
SIBN
Medical Devices Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ABT
| Abbott Laboratories | Cvbskdld | Fjqpmn | $196.9 Bil | |
SYK
| Stryker Corp | Wkbrnkwjnl | Vlht | $136.5 Bil | |
MDT
| Medtronic PLC | Hnxtmpkq | Yzbwmt | $115.4 Bil | |
BSX
| Boston Scientific Corp | Ptngcbxkz | Snqynz | $100.9 Bil | |
EW
| Edwards Lifesciences Corp | Fzdqglmp | Qghmtdl | $57.3 Bil | |
DXCM
| DexCom Inc | Jnshwngj | Tbyf | $53.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Lsqqprbyk | Mcds | $27.2 Bil | |
ALGN
| Align Technology Inc | Fvghgklw | Ypfnc | $24.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Zzrgbqzn | Htsrqcc | $18.4 Bil | |
PODD
| Insulet Corp | Sybzfmrbvf | Djnvq | $11.8 Bil |